top of page
  • Recruiting
    • Dec 19, 2019

NCT04131309: Phase 2: EMN 22 - Daratumumab Monotherapy in Stage 3B Light Chain (AL) Amyloidosis

NCT04131309: Phase 2: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

EMN 22 DARA AMYLOIDOSIS

NCT04131309: Phase 2: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis


This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed stage 3B light chain (AL) amyloidosis.


Sponsor

European Myeloma Network


Collaborator

Janssen Pharmaceutical

 

ClinicalTrials.gov Identifier: NCT04131309

Official Title: Phase 2 Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

First Posted : October 18, 2019

Click here to see details on ClinicalTrials.gov